KCM
XLRN

Kingdon Capital Management’s Acceleron Pharma XLRN Stock Holding History

Kingdon Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-65,000
Closed -$8.16M – 95
2021
Q2 		$8.16M Buy
+65,000
New +$8.2M 1.24% 38
2021
Q1 		– Sell
-15,000
Closed -$1.92M – 87
2020
Q4 		$1.92M Sell
15,000
-229,249
-94% -$26.9M 0.3% 54
2020
Q3 		$27.5M Sell
244,249
-13,000
-5% -$1.29M 3.96% 10
2020
Q2 		$24.5M Buy
257,249
+46,211
+22% +$4.45M 3.63% 10
2020
Q1 		$19M Buy
+211,038
New +$16.4M 3.74% 6

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return